Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Monopar Therapeutics Inc
MNPRCurrent price
3.94 USD
-0.2 USD (-4.83%)
Last closed
4.16 USD
Company
www.monopartx.com
ISIN
US61023L1089
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
13 588 628 USD
Yield for 12 month
+27.30 %
1Y
3Y
5Y
10Y
15Y
MNPR
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC. Address: 1000 Skokie Boulevard, Wilmette, IL, United States, 60091
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
18 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Key Figures MNPR
1 year
3 years
5 years
10 years
EBITDA
–
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-53.45 %
PEG Ratio
–
Return On Equity TTM
-102.31 %
Wall Street Target Price
18 USD
Revenue TTM
–
Book Value
1.73 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-2.3 USD
Diluted Eps TTM
-2.3 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics MNPR
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History MNPR
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:5
Payout Ratio
–
Last Split Date
13.08.2024
Dividend Date
–
Stock Valuation MNPR
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-2.4233
Price Book MRQ
2.2312
Financials MNPR
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators MNPR
For 52 weeks
1.37 USD
8.65 USD
50 Day MA
2.97 USD
Shares Short Prior Month
29 807
200 Day MA
3.02 USD
Short Ratio
0.74
Shares Short
92 795
Short Percent
19.02 %
BeatStart